Urigen granted key US patent for PBS drug

The USA's Urigen Pharmaceuticals says that the US Patent and Trademark Office has issued the first patent for the use of URG101, an investigational, bladder instillation treatment for painful bladder syndrome. US patent number 7,414,039 broadly covers the use of URG101 in the treatment of the condition until 2025.

Urigen announced positive results from a Phase II, multicenter, double-blind, placebo-controlled, crossover trial. Findings from the study included: primary endpoint - improvement in average daytime pain (p=0.03). Secondary endpoints - improvement in daytime urgency (p=0.03) and total symptom score (p=0.03).